Table 2.
Univariate analysis of cytokine levels in patients with prostate cancer during course of radiotherapy.
| Concentration [pg/mL] | Pre-treatment | After 5th fraction | After 15th fraction | After 25th fraction | After last fraction | After 1 month | b | p |
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | ||||||||
| IL-1β | 1.2 (0.1–4.1) | 1.0 (0.2–4.3) | 1.3 (0.3–4.2) | 1.3 (0.3–4.3) | 1.2 (0.3–4.5) | 1.2 (0.2–4.8) | 0.018 | 0.712 |
| IL-2 | 1.9 (0.2–27.9) | 1.8 (0.2–17.8) | 1.6 (0.3–32.2) | 2.1 (0.3–26.1) | 1.8 (0.2–36.4) | 1.8 (0.2–18.8) | 0.018 | 0.081 |
| IL-6 | 2.6 (0.3–14.3) | 2.5 (0.2–29.3) | 2.4 (0.2–40.0) | 2.6 (0.2–33.8) | 1.9 (0–58.6) | 2.5 (0.1–17.3) | 0.018 | 0.039 |
| IFN-γ | 8.1 (2.2–96.3) | 9.8 (1.3–52.1) | 8.8 (1.3–78.0) | 8.3 (1.8–90.5) | 8.4 (1.3–107.7) | 6.8 (1.9–52.9) | 0.004 | 0.138 |
| TGF-β1 | 42.7 (4.3–155.0) | 43.1 (4.2–91.0) | 46.3 (4.9–149.7) | 44.6 (5.9–150.3) | 45.6 (1.5–120.7) | 41 (2.8–193.5) | 0.001 | 0.516 |
*Multilevel ordinal regression models with the degree of acute genitourinary toxicity as the dependent variable, adjusted for the time point and the type of treatment. Depending on the type of variables and the normality of distribution, data are shown as median (min–max).